Skip to main content

5 Result(s)

within Jan C. Buckner Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

    An oral formulation of temsirolimus (Torisel®), an inhibitor of the mammalian target of rapamycin, was evaluated on an intermittent schedule (once daily for 5 days every 2 weeks) in patients with advanced canc...

    Jan C. Buckner, Bahram Forouzesh, Charles Erlichman… in Investigational New Drugs (2010)

  2. No Access

    Article

    Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial

    Purpose: Novel therapeutic agents in the treatment of recurrent gliomas are urgently needed. Pyrazoloacridine (PZA), a rationally synthesized acridine derivative, has shown promising antitumor activity against gl...

    Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer… in Investigational New Drugs (2005)

  3. No Access

    Article

    A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas

    Current systemic treatment options for patientswith relapsed gliomas are limited. Thetopoisomerase I inhibitor topotecan has demonstrated broadantitumor activity in both preclinicalstudies as well as a number ...

    Patrick A. Burch, Albert M. Bernath, Terrence L. Cascino… in Investigational New Drugs (2000)

  4. No Access

    Article

    Phase I study of combined alpha Interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy

    Interferon (IFN) and conventional cytotoxic chemotherapeutic agents have been successfully combined in various studies. Alpha difluoromethylornithine (DFMO) is a novel antitumor agent which is an inhibitor of ...

    Vinod Ganju, John H. Edmonson, Jan C. Buckner in Investigational New Drugs (1994)

  5. No Access

    Article

    Phase II evaluation of menogaril in patients with advanced hypernephroma

    Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progress...

    Harry J. Long III, Mark D. Hauge, Terry M. Therneau… in Investigational New Drugs (1991)